Rosetta Genomics Receives U.S. Patent for Treatment of Prostate Cancer
September 22 2015 - 8:57AM
Business Wire
Further strengthens patent portfolio in
molecular diagnostics and therapeutics in urologic cancers
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and
provider of microRNA-based and other molecular diagnostics,
announces receipt of a Notice of Allowance from the United States
Patent and Trademark Office (USPTO) for U.S. Patent Application No.
14/446,505, titled “Compositions and Methods for the Prognosis
and Treatment of Prostate Cancer.”
The patent claims the treatment of prostate cancer through the
administration of anti-hsa-miR-210 or a sequence having 80%
identity thereto, as well as a method for inhibiting the growth or
viability of prostate cancer cells using anti-hsa-miR-210 or a
sequence having 80% identity thereto.
In June 2014, the Company announced receipt of a separate Notice
of Allowance from the USPTO for U.S. Patent Application No.
13/390,995, entitled ”Compositions and Methods for Prognosis and
Treatment of Prostate Cancer,” which claims cover the expression of
miR-205 as an indicator of good prognosis and relates to methods
and kits for prognosis of prostate cancer.
“When issued, this new U.S. patent will fortify Rosetta
Genomics’ leadership in microRNA technology and expand our
footprint in urological cancers. Through our acquisition of
PersonalizeDx, we offer FISH, IHC and PCR-based testing
capabilities in urologic and other cancers, which provide content
and platforms that complement our microRNA offerings to provide
clinicians with valuable information to guide treatment decisions.
This patent is important as this biomarker, over-expressed in
primary prostate tumors, could be used as a therapeutic target for
prostate cancer. We look forward to monetizing this new
intellectual property,” noted Kenneth A. Berlin, President and
Chief Executive Officer of Rosetta Genomics. “We remain committed
to strengthening and expanding our intellectual property portfolio
to protect and broaden our ability to provide actionable genomic
information when it matters most.”
About Prostate Cancer
Prostate cancer is the most common non-cutaneous cancer in
males, with 1 of every 7 men being diagnosed during his lifetime,
and is the second most common cause of cancer-related death in men
in the United States. The American Cancer Society estimates that in
2014 about 233,000 new cases of prostate cancer will be diagnosed
and about 29,480 men will die of prostate cancer.
About Rosetta Genomics
Rosetta develops and commercializes a broad range of
microRNA-based and other high-value molecular diagnostics.
Rosetta’s integrative research platform combining bioinformatics
and state-of-the-art laboratory processes has led to the discovery
of hundreds of biologically validated novel human microRNAs.
Building on its strong patent position and proprietary platform
technologies, Rosetta is working on the application of these
technologies in the development and commercialization of a full
range of microRNA-based diagnostic tools. Through the acquisition
of PersonalizeDx, the Company also offers core FISH, IHC and
PCR-based testing capabilities and partnerships in oncology and
urology that provide additional content and platforms that
complement the Rosetta offerings. Rosetta’s cancer testing services
are commercially available through the Philadelphia, PA- and Lake
Forest, CA-based CAP-accredited, CLIA-certified labs. For more
information visit www.rosettagenomics.com.
Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta’s future
expectations, plans and prospects including, but not limited
to statements relating to Rosetta Genomics patent position and
its strengthening, expansion and monetization of its intellectual
property, as well as the importance of miR-210 in prostate cancer,
constitute forward-looking statements for the purposes of the safe
harbor provisions under The Private Securities Litigation Reform
Act of 1995. Actual results may differ materially from those
indicated by these forward-looking statements as a result of
various important factors, including those risks more fully
discussed in the "Risk Factors" section of Rosetta’s Annual Report
on Form 20-F for the year ended December 31, 2014 as filed
with the SEC. In addition, any forward-looking statements represent
Rosetta’s views only as of the date of this release and should not
be relied upon as representing its views as of any subsequent date.
Rosetta does not assume any obligation to update any
forward-looking statements unless required by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150922005803/en/
Company:Rosetta GenomicsKen Berlin, 609-419-9003President
& CEOinvestors@rosettagenomics.comorInvestors:LHAAnne
Marie Fields, 212-838-3777afields@lhai.comorBruce Voss,
310-691-7100bvoss@lhai.com
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Apr 2023 to Apr 2024